EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xenon Pharmaceuticals's Enterprise Value is $2,390.88 Mil.
Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-214.05 Mil. Therefore, Xenon Pharmaceuticals's EV-to-EBIT for today is -11.17.
The historical rank and industry rank for Xenon Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
XENE'
s EV-to-EBIT Range Over the Past 10 Years
Min: -32.58 Med: -7.38 Max: 89.8
Current: -11.17
During the past 13 years, the highest EV-to-EBIT of Xenon Pharmaceuticals was 89.80. The lowest was -32.58. And the median was -7.38.
XENE's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs XENE: -11.17
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Xenon Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $2,844.41 Mil.
Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-214.05 Mil. Xenon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7.53%.
Xenon Pharmaceuticals EV-to-EBIT Historical Data
The historical data trend for Xenon Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xenon Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenon Pharmaceuticals EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's EV-to-EBIT falls into.
Xenon Pharmaceuticals EV-to-EBIT Calculation
Xenon Pharmaceuticals's EV-to-EBIT for today is calculated as:
Xenon Pharmaceuticals's current Enterprise Value is $2,390.88 Mil.
Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-214.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xenon Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $2,844.41 Mil.
Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-214.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XENE has been successfully added to your 